In certain severe asthma conditions, biologics such as omalizumab (anti‐IgE), mepolizumab, reslizumab and benralizumab (anti‐IL‐5 pathways), and dupilumab (anti‐IL‐4/IL‐13) represent major advances in asthma care [63]. Here, IL4 is linked to asthma.